While these drugs can be effective for many patients, some don’t respond favorably. Certain patients don’t see much improvement, or they can’t tolerate the side effects. Moreover, tranquilizers like Valium and Xanax can be highly addictive. Clearly, alternative treatments are warranted. Could cannabidiol (CBD), the most prominent non-intoxicating constituent in cannabis, provide a viable alternative for currently available anxiety medications? Quite possibly!
Squeeze the top of your dropper to fill CBD oil into the pipette. Dispense CBD oil under the tongue and swish it around if you like. Alternatively, you can also let the oil sit under the tongue. CBD oil drops taste better, especially if you have a flavored oil version. Add the number of drops you need to get your daily dose of CBD as instructed by the manufacturer. CBD oil should be absorbed into the body system after holding it in the mouth for 60 to 90 seconds before swallowing.
CBD has a broad pharmacological profile, including interactions with several receptors known to regulate fear and anxiety-related behaviors, specifically the cannabinoid type 1 receptor (CB1R), the serotonin 5-HT1A receptor, and the transient receptor potential (TRP) vanilloid type 1 (TRPV1) receptor [11, 12, 19, 21]. In addition, CBD may also regulate, directly or indirectly, the peroxisome proliferator-activated receptor-γ, the orphan G-protein-coupled receptor 55, the equilibrative nucleoside transporter, the adenosine transporter, additional TRP channels, and glycine receptors [11, 12, 19, 21]. In the current review of primary studies, the following receptor-specific actions were found to have been investigated as potential mediators of CBD’s anxiolytic action: CB1R, TRPV1 receptors, and 5-HT1A receptors. Pharmacology relevant to these actions is detailed below.
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act. This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.